Cue names Daniel Baker interim CDO, CSO Amish Suri to transition to advisor role
The Fly

Cue names Daniel Baker interim CDO, CSO Amish Suri to transition to advisor role

Cue Biopharma (CUE) announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer effective November 25, 2024. Dr. Anish Suri will transition from his current role of president & chief scientific officer and will serve the company as principal research and immunology advisor effective as of the same date. Following his retirement from Janssen in 2019, Dr. Baker served as CEO and founder of Kira Therapeutics and more recently as Executive Director on the board of Galapagos Therapeutics from April 2022 until October 2024.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App